Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Clinical Development Programme

Besides the three phase 1/2 trials  that make up the clinical registration programme for larotrectinib to date, larotrectinib has also been included in two ongoing independent National Cancer Institute (NCI)-supported clinical trials (NCI-MATCH and NCI-COG Pediatric MATCH) that are screening and treating patients based on the genetic alterations in their tumours rather than based on tumour-type [1].

Table 8: Summary of Ongoing Clinical Trials for Larotrectinib

Registry Number





Pediatric MATCH Treatment Trial


Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions


MATCH Screening Trial


Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

These data are current as of 6 June 2019 ( clinicaltrials.gov)


  1. Lassen UN, Albert CM, Kummar S et al. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. Annals of Oncology 2018; 29: mdy279.397-mdy279.397.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings